Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 19, 2016. The document serves as a transaction notification regarding a Person Closely Associated (PCA) with a Principal Director, Manager, or Representative (PDMR).
Key Financial Metrics
This filing does not contain consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It reports a single specific transaction:
- Instrument: GlaxoSmithKline plc American Depositary Shares (ADSs), ISIN: US37733W1053.
- Transaction Volume: 1 ADS.
- Transaction Price: $43.54 per ADS.
- Transaction Date: September 15, 2016.
Material Changes
The filing details an increase of 1 ADS held by Dr. K Slaoui, a PCA of Dr. M M Slaoui (Chairman, Global Vaccines). This increase resulted from the revaluation of the cash element of a notional investment within the GSK 401(K) plan. There are no material changes to the company's overall financial position reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items beyond the routine disclosure of the insider transaction described above.
Investor Verification Points
- Verify the identity of Dr. K Slaoui and their relationship to Dr. M M Slaoui.
- Confirm the transaction was a notional allocation within the GSK 401(K) plan rather than an open market purchase.
- Note that this filing does not provide data on GSK's broader financial performance for the period.